Security
Harmony Biosciences Holdings, Inc. Common Stock · HRMY
HRMYNASDAQCommon stockCurrentCIK 1802665Updated Oct 14, 2026
HRMY price & chart
Loading TradingView…
NASDAQ:HRMY on TradingView ↗About the company
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
In the news
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
144 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding Harmony Biosciences Holdings, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,271,631,000Source | 999,200,000Source | 811,448,000Source | 673,870,000Source |
| Property, Plant and Equipment, NetUSD | — | 1,257,000Source | 371,000Source | 573,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 89,418,000Source | 113,263,000Source | 137,108,000Source | 160,953,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 752,502,000Source | 453,001,000Source | 311,660,000Source | 243,784,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 96,787,000Source | 83,033,000Source | 74,140,000Source | 54,740,000Source |
| Inventory, NetUSD | 5,357,000Source | 7,198,000Source | 5,363,000Source | 4,297,000Source |
| Assets, CurrentUSD | 907,014,000Source | 579,252,000Source | 451,070,000Source | 400,285,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,344,000Source | 2,122,000Source | 2,344,000Source | 2,312,000Source |
| Other Assets, NoncurrentUSD | 18,373,000Source | 5,886,000Source | 6,298,000Source | 2,798,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 401,413,000Source | 340,045,000Source | 344,456,000Source | 271,032,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Retained Earnings (Accumulated Deficit)USD | 160,903,000Source | 2,216,000Source | -143,277,000Source | -272,130,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 346,000Source | 66,000Source | 2,000Source | -151,000Source |
| Stockholders' Equity Attributable to ParentUSD | 870,218,000Source | 659,155,000Source | 466,992,000Source | 402,838,000Source |
| Additional Paid in Capital, Common StockUSD | 708,968,000Source | 656,872,000Source | 610,266,000Source | 675,118,000Source |
| Liabilities and EquityUSD | 1,271,631,000Source | 999,200,000Source | 811,448,000Source | 673,870,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 252,132,000Source | 175,082,000Source | 163,781,000Source | 78,884,000Source |
| Operating Lease, Liability, CurrentUSD | 1,073,000Source | 1,318,000Source | 1,437,000Source | 1,614,000Source |
| Accounts Payable, CurrentUSD | 17,693,000Source | 13,744,000Source | 17,730,000Source | 3,786,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,512,000Source | 822,000Source | 1,082,000Source | 975,000Source |
| Other Liabilities, NoncurrentUSD | 5,618,000Source | 1,947,000Source | 2,109,000Source | 2,501,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 191,039,000Source | 120,640,000Source | — | 59,942,000Source |
| Long-term Debt, Current MaturitiesUSD | 20,000,000Source | 16,250,000Source | 15,000,000Source | 2,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 143,663,000Source | 163,016,000Source | 178,566,000Source | 189,647,000Source |
| Short-term InvestmentsUSD | 22,838,000Source | 14,185,000Source | 41,800,000Source | 79,331,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 158,687,000Source | 145,493,000Source | 128,853,000Source | 181,468,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 44,895,000Source | 42,602,000Source | 31,705,000Source | 26,173,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 13,754,000Source | 8,893,000Source | 19,400,000Source | 19,897,000Source |
| Increase (Decrease) in InventoriesUSD | -1,841,000Source | 1,835,000Source | 1,066,000Source | -135,000Source |
| Deferred Income Tax Expense (Benefit)USD | 40,699,000Source | -29,298,000Source | -14,994,000Source | 10,423,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 348,199,000Source | 219,821,000Source | 219,387,000Source | 144,466,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 36,967,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -39,649,000Source | -67,484,000Source | -46,439,000Source | -141,832,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 310,000Source | 1,153,000Source | 312,000Source | 172,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 3,004,000Source | 2,497,000Source | 514,000Source | — |
| Payments for Repurchase of Common StockUSD | — | — | 100,000,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -9,049,000Source | -10,996,000Source | -105,552,000Source | 6,841,000Source |
| Repayments of Long-term DebtUSD | 16,250,000Source | 15,000,000Source | 4,750,000Source | 2,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 299,501,000Source | 141,341,000Source | 67,396,000Source | 9,475,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 752,772,000Source | 453,271,000Source | 311,930,000Source | 244,534,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 14,685,000Source | 17,317,000Source | 20,051,000Source | 16,364,000Source |
| Income Taxes Paid, NetUSD | 19,820,000Source | 79,635,000Source | 48,233,000Source | 12,645,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 44,960,000Source | 42,701,000Source | 31,206,000Source | 26,905,000Source |
| Amortization of Debt Issuance CostsUSD | 647,000Source | 700,000Source | 3,246,000Source | 1,663,000Source |
| Amortization of Intangible AssetsUSD | 23,845,000Source | 23,845,000Source | 23,845,000Source | 22,966,000Source |
| DepreciationUSD | — | 267,000Source | 514,000Source | 419,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -9,766,000Source | — |
| General and Administrative ExpenseUSD | 152,536,000Source | 110,352,000Source | 95,289,000Source | 84,017,000Source |
| Income Tax Expense (Benefit)USD | 56,377,000Source | 46,311,000Source | 44,543,000Source | -76,782,000Source |
| InterestExpenseNonoperatingUSD | 14,649,000Source | 17,496,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 158,687,000Source | 145,493,000Source | 128,853,000Source | 181,468,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 128,853,000Source | 181,468,000Source |
| Operating ExpensesUSD | 461,642,000Source | 367,093,000Source | 268,756,000Source | 234,188,000Source |
| Other Nonoperating Income (Expense)USD | -680,000Source | -68,000Source | 159,000Source | 169,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 200,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 10,205,000Source | 6,501,000Source | 5,055,000Source | 8,841,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 868,453,000Source | 714,734,000Source | 582,022,000Source | 437,855,000Source |
| Cost of RevenueUSD | 198,342,000Source | 156,815,000Source | 121,236,000Source | 83,481,000Source |
| Operating Income (Loss)USD | 208,469,000Source | 190,826,000Source | 192,030,000Source | 120,186,000Source |
| Other Nonoperating Income (Expense)USD | -680,000Source | -68,000Source | 159,000Source | 169,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 215,064,000Source | 191,804,000Source | 173,396,000Source | 104,686,000Source |
| Income Tax Expense (Benefit)USD | 56,377,000Source | 46,311,000Source | 44,543,000Source | -76,782,000Source |
| Net Income (Loss) Attributable to ParentUSD | 158,687,000Source | 145,493,000Source | 128,853,000Source | 181,468,000Source |
| Earnings Per Share, BasicUSD per share | 2.76Source | 2.56Source | 2.17Source | 3.07Source |
| Earnings Per Share, DilutedUSD per share | 2.71Source | 2.51Source | 2.13Source | 2.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 57,492,277Source | 56,885,455Source | 59,469,648Source | 59,173,121Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 58,544,570Source | 57,869,915Source | 60,372,397Source | 61,097,045Source |
| Interest Expense (non-operating)USD | 14,649,000Source | 17,496,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 23,845,000Source | 23,845,000Source | 23,845,000Source | 22,966,000Source |
| Current Income Tax Expense (Benefit)USD | 15,678,000Source | 74,311,000Source | 57,962,000Source | 9,161,000Source |
| General and Administrative ExpenseUSD | 152,536,000Source | 110,352,000Source | 95,289,000Source | 84,017,000Source |
| Gross ProfitUSD | 670,111,000Source | 557,919,000Source | 460,786,000Source | 354,374,000Source |
| Interest ExpenseUSD | — | — | 23,757,000Source | — |
| Interest Expense, DebtUSD | 14,649,000Source | 17,496,000Source | 23,757,000Source | 18,795,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | -15,669,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 128,853,000Source | 181,468,000Source |
| Operating ExpensesUSD | 461,642,000Source | 367,093,000Source | 268,756,000Source | 234,188,000Source |
| Research and Development ExpenseUSD | 189,594,000Source | 145,825,000Source | 76,063,000Source | 70,886,000Source |
| Selling and Marketing ExpenseUSD | 119,512,000Source | 110,916,000Source | 97,404,000Source | 79,285,000Source |
Filing attachments
hrmy-ex99d1.htm · 8-K · 2026-10-13
Exhibit 99.1 Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. Current CEO Jeffrey M. Dayno, M.D., will retire at the end of the year following a nine-year tenure at the Company, including as Chief Medical Officer, and step down as a member of the B…
Read attachment ↗hrmy-20260804xex99d1.htm · 8-K · 2026-08-04
EX-99.1 2 hrmy-20260804xex99d1.htm EX-99.1 Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1. 0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Sa…
Read attachment ↗hrmy-20260804xex99d2.htm · 8-K · 2026-08-04
EX-99.2 3 hrmy-20260804xex99d2.htm EX-99.2 Copyright © 2026 Harmony Biosciences. All rights reserved. Q2 2026 Financial Results and Business Update August 4, 2026 ────────────────────────────────────────────────────────────── Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact sh…
Read attachment ↗hrmy-20260716xex99d1.htm · 8-K · 2026-07-16
EX-99.1 3 hrmy-20260716xex99d1.htm EX-99.1 Exhibit 99.1 Harmony Biosciences PREANNOUNCES Record QuarterLY Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 PLYMOUTH MEETING, Pa. - July 16, 2026 -…
Read attachment ↗hrmy-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 hrmy-20260507xex99d1.htm EX-99.1 Exhibit 99.1 HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management A…
Read attachment ↗hrmy-20260507xex99d2.htm · 8-K · 2026-05-07
EX-99.2 3 hrmy-20260507xex99d2.htm EX-99.2 Copyright © 2026 Harmony Biosciences. All rights reserved. Q1 2026 Financial Results and Business Update May 7, 2026 ────────────────────────────────────────────────────────────── Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should…
Read attachment ↗